BPC-157 Both Prevents and Reverses Alcohol-Induced Liver Damage and Portal Hypertension
BPC-157 both prevented and reversed alcohol-induced portal hypertension and liver lesions in rats, demonstrating remarkable hepatoprotective effects against chronic alcohol damage.
Quick Facts
What This Study Found
BPC-157 both prevented (when co-administered) and reversed (when given after damage) chronic alcohol-induced portal hypertension and liver lesions in rats, measured by direct portal vein pressure and histological assessment.
Key Numbers
How They Did This
Animal study in rats. Chronic alcohol administration (7.28 g/kg/day in drinking water). BPC-157 given preventively (with alcohol) or therapeutically (after liver damage established). Portal vein pressure measured directly. Liver histology assessed.
Why This Research Matters
Alcoholic liver disease is a leading cause of liver failure and death. A peptide that both prevents AND reverses liver damage could save millions of lives, especially since most liver drugs only slow progression.
The Bigger Picture
Most liver disease treatments only slow damage. BPC-157's ability to reverse established portal hypertension and liver lesions suggests it may activate repair mechanisms that existing drugs cannot.
What This Study Doesn't Tell Us
Rat alcohol model. The mechanism of hepatoprotection was not determined. Whether BPC-157 can reverse advanced cirrhosis (not just early lesions) is unknown. Human data absent.
Questions This Raises
- ?Could BPC-157 treat alcoholic liver disease in humans?
- ?What mechanism mediates the portal pressure reduction?
- ?Does BPC-157 promote liver regeneration or prevent ongoing damage?
Trust & Context
- Key Stat:
- Prevents AND reverses BPC-157 both prevented liver damage when given with alcohol AND reversed it after damage was established — dual-direction hepatoprotection
- Evidence Grade:
- Preliminary animal evidence with direct hemodynamic measurements (portal pressure) and histological confirmation, demonstrating both prevention and reversal.
- Study Age:
- Published in 2001. BPC-157's hepatoprotective effects have been further confirmed in subsequent animal studies.
- Original Title:
- Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.
- Published In:
- Journal of physiology, Paris, 95(1-6), 315-24 (2001)
- Authors:
- Prkacin, I(13), Separovic, J(12), Aralicia, G, Perovic, D, Gjurasin, M, Lovric-Bencic, M, Stancic-Rokotov, D, Staresinic, M, Anic, T, Mikus, D, Sikiric, P, Seiwerth, S, Mise, S, Rotkvic, I, Jagic, V, Rucman, R, Petek, M, Turkovic, B, Marovic, A, Sebecic, B, Boban-Blagaic, A, Kokic, N
- Database ID:
- RPEP-00692
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can BPC-157 protect the liver from alcohol?
In rats, yes — dramatically. It prevented liver damage when given during alcohol exposure AND reversed existing damage when given after liver injury was established. Both portal hypertension and liver lesions improved.
Could this help alcoholic liver disease patients?
The animal results are remarkably promising. If confirmed in humans, BPC-157 could be valuable for both preventing liver damage in heavy drinkers and treating established alcoholic liver disease. Human trials are needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00692APA
Prkacin, I; Separovic, J; Aralicia, G; Perovic, D; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Staresinic, M; Anic, T; Mikus, D; Sikiric, P; Seiwerth, S; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sebecic, B; Boban-Blagaic, A; Kokic, N. (2001). Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.. Journal of physiology, Paris, 95(1-6), 315-24.
MLA
Prkacin, I, et al. "Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.." Journal of physiology, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Portal hypertension and liver lesions in chronically alcohol..." RPEP-00692. Retrieved from https://rethinkpeptides.com/research/prkacin-2001-portal-hypertension-and-liver
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.